TrialAntimicrobial agents and chemotherapy2007

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.

Patrick F Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.